Results 221 to 230 of about 432,253 (365)

Utilization of Nicotinic Acid and its Amide by the Human Erythrocyte in Vitro¹

, 1948
Edgar Leifer, John R. Hogness, Lloyd J. Roth, Wright H. Langham   +3 more
openalex   +2 more sources

Targeting PTBP3‐Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis

Advanced Science, EarlyView.
The splicing factor PTBP3 promotes COX11 exon skipping, allowing gastric cancer organoids to evade cuproptosis. Antisense oligonucleotide drugs targeting PTBP3‐mediated COX11 alternative splicing, in combination with copper ionophores, promote cuproptosis in organoids, thereby providing a therapeutic approach for gastric cancer peritoneal metastasis ...
Yajing Zhou, Chao Dong, Xiaochun Shen, Pengbo Wang, Tao Chen, Weikang Li, Xiaotong Sun, Peiyuan Li, Chengxiang Xu, Kaipeng Duan, Dongbao Li, Jin Zhou   +11 more
wiley   +1 more source

Assay of cardiopulmonary bypass system for porcine alveolar macrophages removing GFP-<i>E. coli</i> from erythrocyte surfaces. [PDF]

PeerJ
Liu Y, Wang N, Ru Q, Fan K, Sun N, Sun P, Li H, Yin W.   +7 more
europepmc   +1 more source

DIFFUSION AND PERMEATION OF CATIONS IN HUMAN AND DOG ERYTHROCYTES [PDF]

, 1957
E. J. Harris, T. A. J. Prankerd
openalex   +1 more source

Metal–Organic Frameworks: Unlocking New Frontiers in Cardiovascular Diagnosis and Therapy

Advanced Science, EarlyView.
Metal–organic frameworks (MOFs), are composed of metal ions and bridging organic ligands, are recognized as an excellent platform for host‐gust chemistry. Its rich structural composition, modifiable sites, and multilevel pore distribution can provide delivery and release of signaling molecules, probes, and therapeutic drugs, which exhibit great medical
Qilu Wu, Yuxiao Feng, Mathilde Lepoitevin, Meng Yu, Christian Serre, Jun Ge, Yuan Huang   +6 more
wiley   +1 more source

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source

Assessment of membrane and metabolic parameters of erythrocytes exposed to selected bromophenols. [PDF]

Sci Rep
Jarosiewicz M, Duchnowicz P, Bukowska B.
europepmc   +1 more source

Survival after Transfusion of Rh-positive Erythrocytes Previously Incubated with Rh Antibody [PDF]

, 1949
P. L. Mollison, J. C. S. Paterson
openalex   +1 more source

Inhibition of Ferroptosis Delays Aging and Extends Healthspan Across Multiple Species

Advanced Science, EarlyView.
This study identifies ferroptosis as a key driver of cellular senescence, with its inhibition delaying aging and extending healthspan across species. During senescence, ferroptosis worsens, increasing oxidative stress and lipid peroxidation, which accelerate aging.
Hai‐Jun Fu, Xing‐Yue Zhou, Da‐Lian Qin, Qan Qiao, Qiao‐Zhi Wang, Shi‐Ying Li, Yun‐Fei Zhu, Ya‐Ping Li, Jiang‐Min Zhou, Hui Cai, Fei‐Hong Huang, Lu Yu, Long Wang, An‐Guo Wu, Jian‐Ming Wu, Xiao‐Gang Zhou   +15 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source